The Safety and Efficacy of Carotid Body Modulation Therapy in Hypertensive Patients by External Ultrasonic Micro-bubble

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-01

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators intend to find a noninvasive method for CB modulation therapy and find a simple and convenient indicator for assessing CB activity. This study was designed to evaluate the safety and efficacy of carotid body modulation therapy in hypertensive patients by external ultrasonic micro-bubble and also identify the association between CB volume and CB activity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Digital Intervention on Self-management of Hypertensive Patients at High Risk of Stroke

NCT07089810

Hypertension Mhealth

NOT_YET_RECRUITING NA

Efficacy of Education Via Phone-based Text Messaging (SMS) on Patients With Uncontrolled Hypertension

NCT05711004

Hypertension

UNKNOWN NA

High-Intensity Interval Versus Moderate-Intensity Continuous Water Based Exercise in Hypertensive Older Individuals

NCT04126785

Hypertension

RECRUITING NA

Study on Internet Medical Models for the Management of Patients With Hypertension in China

NCT03527563

Hypertension

UNKNOWN NA

Etiological Classification-guided Individual Intervention in Primary Hypertension

NCT06941935

Hypertension

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Carotid body (CB) hyperactivity, with excessive afferent discharge signal to the respiratory centre anautonomic sympathetic nuclei, can result in hyperventilation and sympathetic hyperactivity. And previous studies have found that CB hyperactivity was common in several kinds of cardiovascular diseases and the investigators also found that CB was obviously enlargement in hypertension and other cardiovascular diseases. Hence, CB might play an important role in the development of these cardiovascular diseases. Moreover, Resection of CB or blockade of P2X3 receptors in CB significantly reduced blood pressure (BP) and muscle sympathetic nerve activity (MSNA) in patients with hypertension. Therefore, CB may be a promising therapeutic target for hypertension. However, the following questions about CB are needed to be addressed urgently. First, the CB volume enlargement may be a promising indicator for selection appropriate patients for CB modulation therapy, but its relationship with the CB hyperactivity is still unclear. Second, although CB resection could significantly reduce BP in hypertensive patients, but the invasive therapy and completely resection may result in severe adverse events.

Based on the aforementioned questions, to find a simple and convenient indicator for assessing CB activity and find a noninvasive method for CB modulation therapy, the investigators designed this study to identify the association between CB volume and CB activity in hypertensive patients and also evaluated the safety and efficacy of carotid body modulation therapy in hypertensive patients by external ultrasonic micro-bubble.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

primary hypertensive patients

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Health volunteers

Evaluate the CB activity of health volunteers as the control

Group Type OTHER

External Ultrasonic Micro-bubble

Intervention Type DEVICE

The enrollmented hypertensive patients should aceepted CB modulation therapy by external ultrasonic micro-bubble

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

External Ultrasonic Micro-bubble

The enrollmented hypertensive patients should aceepted CB modulation therapy by external ultrasonic micro-bubble

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypertensive patients for CB modulation therapy

1. Two or more antihypertensive medications that had been prescribed at least 50% of the manufacturer's maximum dose for at least 2 consecutive weeks before study; Patients take an angiotensin-converting enzyme inhibitor (ACEI) (or angiotensin-ⅱ receptor antagonist (ARB)) and calcium channel blocker (CCB) (or thiazide diuretic) ; Office systolic blood pressure (SBP)≥150 mmHg and \<180mmHg.

2.24-hour ambulatory systolic blood pressure: ≥135 mmHg and \<170 mmHg

3.A history of primary hypertension was recorded. 4.Patients who can understand the purpose of the trial, voluntarily participate and sign informed consent, and are willing to cooperate with clinical follow-up
* Patients for CB Volume and activity evaluation Hypertension group

1. Primary hypertension patients agrees to take part in this study and perform CB MRI, ultrasound, CB activity tests and sign the informed consent.
2. The office blood pressure of patients ≥ 140/90 mmHg; the patents were diagnosed hypertension and are taking anti-hypertensive drugs could also include, although the office blood pressure \< 140/90 mmHg.
3. The CB could be detected by carotid ultrasound or MRI. Control group



1. The volunteers agree to take part in this study and perform CB MRI, ultrasound, CB activity tests and sign the informed consent.
2. The volunteers are healthy.

Exclusion Criteria

* Hypertensive patients for CB modulation therapy

1. Carotid body anatomy is not eligible for treatment: ultrasound examination before treatment fail to find carotid body at carotid artery bifurcation.
2. Carotid body anatomical heterotopic is difficult to select or unsuitable for ultrasound irradiation.
3. Carotid anatomy that does not meet treatment conditions: severe carotid stenosis or occlusion.
4. Carotid ulcer.
5. Severe tortuosity of carotid artery
6. After carotid artery stenting or stripping
7. Other conditions that are not suitable for carotid intervention
8. Glomerular filtration rate (eGFR) \<45 mL/min / 1.73 m2
9. Have type 1 diabetes or poorly controlled type 2 diabetes (defined as plasma HbA1c≥ 9.0% or 24-hour urinary protein quantity \>1g/24h or proliferative retinal lesions)
10. postural hypotension.
11. Recent vascular events: Experienced acute myocardial infarction, unstable angina, syncope, or cerebrovascular accident within 3 months of the screening period.
12. Suspected secondary hypertension.
13. Respiratory support: The individual requires long-term oxygen support or mechanical ventilation (except for nighttime breathing support only because of sleep apnea).
14. Life expectancy \<1 year.
15. A woman who is pregnant, breastfeeding, or planning to become pregnant.
16. Subjects who are currently enrolled in another clinical trial and have not completed the primary endpoint.
17. Allergic to contrast media.
18. The investigators judged the patients' poor compliance and other reasons for not being suitable for participants in the trial.
19. Any other conditions that the investigator did not consider appropriate to participate in the trial.
* Patients for CB Volume and activity evaluation

1. the CB could not be detected by carotid ultrasound or MRI.
2. The patients have secondary hypertension, heart failure.
3. The patients have type 1diabetes mellitus, CB tumor.
4. The patients were diagnosed as OSAS.
5. The patients have severe chronic constructive pulmonary disease, interstitial lung disease or other severe lung diseases.
6. Women who are pregnant, breastfeeding, or planning to become pregnant.
7. Patients with other conditions which are not appropriate for enrollment judged by the investigators.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes